Michael S. Poirier's most recent trade in Qualigen Therapeutics Inc was a trade of 375,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 11, 2022.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Qualigen Therapeutics Inc | Michael S. Poirier | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2022 | 375,000 | 375,000 | - | - | Stock Option (Right to Buy) | |
Qualigen Therapeutics Inc | Michael S. Poirier | Director, Chairman and CEO | Purchase of securities on an exchange or from another person at price $ 0.57 per share. | 22 Jun 2022 | 30,000 | 199,202 | - | 0.6 | 17,100 | Common Stock |
Qualigen Therapeutics Inc | Michael S. Poirier | Director, Chairman, CEO & President | Purchase of securities on an exchange or from another person at price $ 1.80 per share. | 20 Apr 2021 | 11,005 | 11,005 | - | 1.8 | 19,809 | Common Stock |
Qualigen Therapeutics Inc | Michael S. Poirier | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2020 | 1,000,000 | 1,000,000 | - | - | Stock Option (Right to Buy) |